BICYCLE THERAPEUTICS PLC
No enriched coverage for $BCYC in the last 7 days.
No SEC Form 4 filings for $BCYC in the last 30 days.
See all $BCYC insider activity →Bicycle Therapeutics (NASDAQ: BCYC) reported Q2 2026 results and business updates. It cited AACR/ASCO data for nuzefatide in EphA2-expressing cancers, including Phase 2 recurrent pancreatic cancer with first patient dosed in April 2026. Cash was $510.1M at June 30, 2026, funding into 2030. Duravelo-2 interim Week 27 ORR was 65% (17/26).
BICYCLE THERAPEUTICS PLC (BCYC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2621593d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results Data presented at AACR and ASCO provide further validation of the potential of Bicycle ® technology to deliver oncology thera
BICYCLE THERAPEUTICS PLC (BCYC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001761612 X0 00-0000000 true 0001761612 2026-06-17 2026-06-17 0001761612 us-gaap:CommonStockMember 2026-06-17 2026-06-17 0001761612 bcyc:AmericanDepositarySharesMember 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCH
Recent BCYC coverage spans financial news, technology and earnings.
Clinical updates and cash runway into 2030 support a bullish risk-reward setup, but near-term catalysts hinge on ongoing Phase 2 readouts and 2027 BT1702 start.
The filing adds actionable clinical and capital runway details that can shift probability-weighted valuation for BCYC’s lead bicyclic peptide conjugates.
Routine corporate governance outcomes; no new operating, financial, or regulatory catalyst disclosed.
Bicycle Therapeutics announced positive financial results and strategic reprioritization, including pipeline focus and workforce reduction, aiming to extend cash runway into 2030.
Westfield Capital Management's amendment indicates no current ownership or voting rights in Bicycle Therapeutics plc, suggesting no immediate strategic or financial influence.
alphai scores every news story that mentions BCYC with an AI model for sentiment and relevance, and aggregates insider trades from BICYCLE THERAPEUTICS PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Bicycle Therapeutics (NASDAQ: BCYC) reported Q2 2026 results and business updates. It cited AACR/ASCO data for nuzefatide in EphA2-expressing cancers, including Phase 2 recurrent pancreatic cancer with first patient dosed in April 2026. Cash was $510.1M at June 30, 2026, funding into 2030. Duravelo-2 interim Week 27 ORR was 65% (17/26).
6 min readBICYCLE THERAPEUTICS PLC (BCYC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2621593d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results Data presented at AACR and ASCO provide further validation of the potential of Bicycle ® technology to deliver oncology thera
6 min readBICYCLE THERAPEUTICS PLC (BCYC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001761612 X0 00-0000000 true 0001761612 2026-06-17 2026-06-17 0001761612 us-gaap:CommonStockMember 2026-06-17 2026-06-17 0001761612 bcyc:AmericanDepositarySharesMember 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCH
2 min readBicycle Therapeutics reported its Q4 and full-year 2025 financial results, alongside a strategic reprioritization. The company will focus on next-generation therapeutics like BT5528 and Bicycle Radioconjugates, while deprioritizing zelenectide's internal development and converting its trial to a randomized Phase 2 study. This strategic shift includes a 30% workforce reduction to extend its cash runway into 2030, and the company has established partnerships to secure an end-to-end supply chain for its radiopharmaceutical pipeline.
3 min readWestfield Capital Management Company, L.P. filed an Amendment No. 2 to a Schedule 13G, reporting that it beneficially owned 0 shares of Bicycle Therapeutics plc (NASDAQ: BCYC) common stock as of December 31, 2025. The filing indicates no voting or dispositive power held by Westfield for BCYC shares. The amendment was signed by Brandi McMahon, Vice President, Deputy Chief Compliance Officer, and dated March 3, 2026.
1 min readTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
2 min readDelhi, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Global Bicycle Toxin Conjugates Clinical Trials, Proprietary Platforms & Market Opportunity Insight 2025 Report Highlights:
2 min readBicycle Therapeutics Plc ( NASDAQ:BCYC ) , a biotechnology company focused on developing precision-guided therapeutics using its proprietary Bicycle molecule platform, reported its second quarter 2025 earnings on August 8, 2025.
3 min read
